Emergence of antibiotic resistance in upper and lower respiratory tract infections

American Journal of Managed Care

Volumn 5, Issue 11 SUPPL., 1999, Pages

  Jacobs, Michael R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; MACROLIDE; PENICILLIN G; PENICILLINASE; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; DRUG MISUSE; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADULT; CHILD; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; HAEMOPHILUS INFLUENZAE; HUMANS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PRACTICE GUIDELINES; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0032832778     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. IMS National Prescription Audit Plus™ Therapeutic Category Report. Vol 1, December 1997. November 1998.
2. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995;273:214-219.
3. Physician Drug and Diagnosis Audit (PDDA). Scott-Levin PMSI Inc.; Newton, PA; 1997.
4. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278:901-904.
5. Faryna A, Wergowske GL, Goldenberg K. Impact of therapeutic guidelines on antibiotic use by residents in primary care clinics. J Gen Intern Med 1987;2:102-107.
6. Klein JO, Bluestone CD. Management of otitis media in the era of managed care. Adv Pediatr Infect Dis 1996;12:351-386.
7. Teele DW, Klein JO, Rosner BA, and the Greater Boston Otitis Media Study Group. Epidemiology of otitis media during the first seven years of life in children in greater Boston: A prospective, cohort study. J Infect Dis 1989;160:83-94.
8. Kim PE, Musher DM, Glezen WP, et al. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis 1996;22:100-106.
9. Pitkaranta A, Virolainen A, Jero J, Arruda E, Hayden FG. Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 1998;102:291-295.
10. Giebink GS. Vaccination against middle-ear bacterial and viral pathogens. Ann N Y Acad Sci 1997;830:330-352.
11. Uhari M, Hietala J, Tuokko H. Risk of acute otitis media in relation to the viral etiology of infections in children. Clin Infect Dis 1995;20:521-524.
12. Fang G, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990;69:307-316.
13. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J 1996;15:940-943.
14. Zeckel ML, Jacobson JD, Guerra FJ, Therasse DG, Farlow D. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther 1992;14:214-229.
15. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108:43S-52S.
16. Faden H, Duffy L, Wasielewski R, et al. Relationship between nasopharyngeal colonization and the development of otitis media in children. J Infect Dis 1997;175:1440-1445.
17. Gruneberg RN, Felmingham D, and The Alexander Project Group. Results of The Alexander Project: A continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996;25:169-181.
18. Hoberman A, Paradise JL, Block S, et al. Efficacy of amoxicillin/clavulanate for acute otitis media: Relation to Streptococcus pneumoniae susceptibility. Pediatr Infect Dis J 1996;15:955-962.
19. Gwaltney JM. Sinusitis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practices of Infectious Diseases, 4th ed. New York, NY: Churchill Livingstone Inc;1995:585-590.
20. Murray BE. New aspects of antimicrobial resistance and resulting therapeutic dilemmas. J Infect Dis 1991;163:1185-1194.
21. Brotz H, Bierbaum G, Markus A, Molitor E, Sahl HG. Mode of action of the antibiotic mersacidin: Inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother 1995;39:714-719.
22. Clancy J, Dib-Hajj F, Petitpas JW, Yuan W. Cloning and characterization of a novel macrolide efflux gene, mreA, from Streptococcus agalactiae. Antimicrob Agents Chemother 1997;41:2719-2723.
23. Cunha BA, Sea KW. Emergence of antimicrobial resistance in community-acquired pulmonary pathogens. Semin Respir Infect 1998;13:43-53.
24. Enright M, Zawadski P, Pickerill P, Dowson CG. Molecular evolution of rifampicin resistance in Streptococcus pneumoniae. Microb Drug Resist Spring 1998;4:65-70.
25. Murray BE. Problems and mechanisms of antimicrobial resistance. Infect Dis Clin North Am 1989;3:423-439.
26. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995;99(suppl 6B):3S-7S.
27. Jacobs MR, Bajaksouzian S, Lin G, Appelbaum PC. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to oral agents: Results of a 1997 epidemiological study. Presented at the 98th General Meeting of the American Society for Microbiology; May 17-21, 1998; Atlanta, GA. [Abstract A-31].
28. Ronchetti MP, Zilles A, Appelbaum PC, Jacobs MR. Susceptibility of current and archived otitis media isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to contemporary oral agents. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology; September 24-27, 1998; San Diego, CA. [Abstract E-9].
29. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996;25:213-217.
30. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
31. Thornsberry C, Brown SD, Yee YC, et al. Increasing penicillin resistance in Streptococcus pneumoniae in the US. Infect Med 1993;12(suppl):15-24.
32. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y, and the Laboratory Investigator Group. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in the 1996-1997 respiratory season. Diagn Microbial Infect Dis 1997;29:249-257.
33. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40: 1208-1213.
34. Johnston NJ, de Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2425-2426.
35. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996;40: 1817-1824.
36. Schito GC, Mannelli S, Pesce A, and The Alexander Project Group. Trends in the activity of macrolide and ß-lactam antibiotics and resistance development. J Chemother 1997; 9:18-28.
37. Piddock LJV, Hall MC, Wise R. Mechanism of action of lomefloxacin. Antimicrob Agents Chemother 1990;34: 1088-1093.
38. Domagala JM, Hanna LD, Heifetz CL, et al. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J Med Chem 1986; 29:394-404.
39. Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:1177-1182.
40. Pelton SI. Defining resistance: Breakpoints and beyond: Implications for pediatric respiratory infection. Diagn Microbiol Infect Dis 1996;25:195-199.
41. Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs 1998; 55:323-330.
42. Cunha BA. Antibiotic resistance control strategies. Crit Care Clin 1998;14:309-327.
43. Jorgensen JH. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect Dis 1992;14:1119-1123.
44. Sykes RB, Matthew M, O'Callaghan CH. R-factor mediated ß-lactamase production by Haemophilus influenzae. J Med Microbiol 1975;8:437-441.
45. Daum RS, Murphey-Corb M, Shapira E, Dipp S. Epidemiology of Rob ß-lactamase among ampicillin-resistant Haemophilus influenzae isolates in the United States. J Infect Dis 1988;157:450-455.
46. Scriver SR, Walmsley SL, Kau CL, et al. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their ß-lactamases. Antimicrob Agents Chemother 1994;38:1678-1680.
47. Jones RN, Jacobs MR, Washington JA, Pfaller MA. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. Diagn Microbiol Infect Dis 1997;27:75-83.
48. Berk SL, Kalbfleisch JH, and The Alexander Project Collaborative Group. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in the USA. J Antimicrob Chemother 1996;38(suppl A):85-96.
49. Kelly L, Hoellman D, Bazaksouzian S, Zilles A, Jacobs M, Appelbaum PC. SB-265805 (LB 20304a), a new broad-spectrum quinolone: Activity compared with 11 compounds against H. influenzae and M. catarrhalis. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology; September 24-27, 1998; San Diego, CA. [Abstract F-106].
50. Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1994;38:594-601.
51. Thornsberry C, Ogilvie PT, Holley HP Jr, Sahm DF. In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: Correlation with penicillin resistance. Clin Ther 1998;20: 1179-1190.
52. Kelly LM, Jacobs MR, Appelbaum PC. Antipneumococcal activity of SB 265805 (a new broad-spectrum quinolone) compared with nine compounds by MlC. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology; September 24-27, 1998; San Diego, CA. [Abstract F-87].
53. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-2080.
54. McGregor K, Chang BJ, Mee BJ, Riley TV. Moraxella catarrhalis: Clinical significance, antimicrobial susceptibility and BRO beta-lactamases. Eur J Clin Microbiol Infect Dis 1998;17:219-234.
55. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-259.
56. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
57. Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: Are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997;176:1253-1259.
58. Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin®) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997;16:463-470.